For fiscal 2024 (ended Dec 31, 2024), MEDIROM Healthcare Technologies Inc. reported ¥8.30B of revenue and ¥148.76M of net income. Figures are in JPY, the currency of its SEC filings.
MRM revenue was ¥8.30B for fiscal 2024 (ended Dec 31, 2024), up 21.5% from fiscal 2023. Compound annual growth was +16.3% over 5 years. It rose in 3 of the last 5 fiscal years. Fiscal 2024 is the highest of the 6 fiscal years on file.
MRM net income was ¥148.76M for fiscal 2024 (ended Dec 31, 2024), up 28.9% from fiscal 2023. Compound annual growth was +53.7% over 5 years.
MRM diluted EPS was ¥28.52 for fiscal 2024 (ended Dec 31, 2024), up 27.7% from fiscal 2023. Compound annual growth was +47.7% over 5 years.
MRM free cash flow was -¥1.40B for fiscal 2024 (ended Dec 31, 2024), compared with -¥767.58M in fiscal 2023.
| Line item | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Revenue | ¥8.30B | ¥6.83B | ¥6.95B | ¥5.41B | ¥3.34B | ¥3.91B |
| Cost of revenue | ¥6.05B | ¥5.26B | ¥5.05B | - | - | - |
| Gross profit | ¥2.25B | ¥1.57B | ¥1.90B | - | - | - |
| Selling, general and admin | ¥2.24B | ¥1.96B | ¥1.81B | ¥1.82B | ¥1.07B | ¥871.86M |
| Operating income | -¥18.10M | -¥391.58M | ¥96.97M | -¥470.59M | -¥746.09M | ¥34.35M |
| Interest expense | ¥49.74M | ¥36.87M | ¥9.80M | ¥11.95M | ¥13.23M | ¥13.59M |
| Pre-tax income | ¥47.71M | ¥20.62M | ¥179.77M | -¥414.48M | -¥626.69M | ¥32.74M |
| Income tax | -¥90.48M | -¥94.43M | ¥30.81M | ¥576.25M | -¥87.52M | ¥15.96M |
| Net income | ¥148.76M | ¥115.40M | ¥148.97M | -¥990.73M | -¥539.17M | ¥17.34M |
| EPS, basic | ¥29.13 | ¥23.64 | ¥30.54 | -¥203.13 | -¥133.97 | ¥4.63 |
| EPS, diluted | ¥28.52 | ¥22.34 | ¥27.23 | -¥203.13 | -¥133.97 | ¥4.06 |
| Diluted shares | 5.9M | 5.2M | 5.5M | 4.9M | 4.0M | 4.3M |
| Line item | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Cash and equivalents | ¥329.40M | ¥106.35M | ¥605.45M | ¥370.62M | ¥1.44B | ¥513.62M |
| Short-term investments | ¥6.16M | ¥26.50M | ¥26.50M | ¥26.53M | ¥32.52M | ¥38.52M |
| Receivables | ¥1.36B | ¥621.87M | ¥534.69M | ¥312.30M | ¥148.54M | ¥337.05M |
| Inventory | ¥151.64M | ¥139.98M | ¥114.11M | ¥18.70M | ¥7.96M | ¥5.51M |
| Current assets | ¥2.71B | ¥1.76B | ¥2.36B | ¥1.38B | ¥2.09B | ¥1.38B |
| Goodwill | ¥389.13M | ¥484.56M | ¥539.49M | ¥600.33M | ¥150.72M | ¥78.28M |
| Total assets | ¥8.09B | ¥6.85B | ¥6.75B | ¥5.75B | ¥5.71B | ¥4.76B |
| Current liabilities | ¥4.18B | ¥3.56B | ¥3.64B | ¥3.20B | ¥2.65B | ¥2.26B |
| Short-term debt | ¥620.81M | ¥100.42M | ¥99.17M | ¥162.25M | ¥242.28M | ¥371.57M |
| Long-term debt | ¥764.20M | ¥1.05B | ¥1.15B | ¥746.59M | ¥668.38M | ¥150.53M |
| Total debt | ¥1.39B | ¥1.15B | ¥1.25B | ¥908.84M | ¥910.66M | ¥522.10M |
| Total liabilities | ¥6.90B | ¥6.63B | ¥6.81B | ¥5.96B | ¥5.22B | - |
| Shareholders' equity | ¥933.27M | ¥210.88M | -¥59.38M | -¥208.34M | ¥491.26M | ¥600.06M |
| Line item | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Operating cash flow | -¥1.33B | -¥631.74M | -¥685.70M | -¥557.23M | -¥366.42M | ¥7.87M |
| Capital expenditures | ¥71.41M | ¥135.84M | ¥120.74M | ¥95.65M | ¥73.56M | ¥7.41M |
| Free cash flow | -¥1.40B | -¥767.58M | -¥806.44M | -¥652.88M | -¥439.98M | ¥464.0K |
| Investing cash flow | ¥361.39M | -¥328.58M | ¥580.44M | -¥83.94M | -¥139.60M | -¥37.93M |
| Financing cash flow | ¥1.19B | ¥461.21M | ¥340.10M | -¥427.95M | ¥1.43B | ¥331.99M |
| Stock-based compensation | - | - | - | ¥196.85M | - | - |
| Depreciation and amortization | ¥290.04M | ¥252.59M | ¥184.06M | ¥126.24M | ¥62.29M | ¥46.17M |
| Line item | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | 21.5% | -1.8% | 28.5% | 61.9% | -14.5% | - |
| Net income growth, YoY | 28.9% | -22.5% | - | - | - | - |
| EPS growth, YoY | 27.7% | -18.0% | - | - | - | - |
| Gross margin | 27.1% | 23.0% | 27.4% | - | - | - |
| Operating margin | -0.2% | -5.7% | 1.4% | -8.7% | -22.3% | 0.9% |
| Net margin | 1.8% | 1.7% | 2.1% | -18.3% | -16.1% | 0.4% |
| Free cash flow margin | -16.9% | -11.2% | -11.6% | -12.1% | -13.2% | 0.0% |
| Return on equity | 15.9% | 54.7% | - | - | -109.8% | 2.9% |
| Return on assets | 1.8% | 1.7% | 2.2% | -17.2% | -9.4% | 0.4% |
| Current ratio | 0.65 | 0.49 | 0.65 | 0.43 | 0.79 | 0.61 |
| Debt to equity | 1.48 | 5.46 | - | - | 1.85 | 0.87 |
Source: XBRL data MEDIROM Healthcare Technologies Inc. files with the SEC, latest filing dated Apr 29, 2025 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MRM | ¥8.30B | +21.5% | ¥148.76M | 1.8% | $2.2M |
| SE | $22.94B | +36.4% | $1.58B | 6.9% | $46.38B |
| IT | $6.44B | -0.2% | $954.41M | 14.8% | $11.99B |
| RTO | $6.91B | +4.4% | $470.00M | 6.8% | $11.91B |
| SCI | $3.31B | +3.4% | $561.30M | 17.0% | $10.02B |
| EDU | $5.66B | +15.5% | $475.17M | 8.4% | $8.53B |
| HRB | $3.95B | +4.9% | $733.60M | 18.6% | $6.46B |
| TAL | $3.01B | +33.7% | $530.75M | 17.6% | $5.63B |
| GHC | $5.12B | +4.3% | $496.96M | 9.7% | $5.05B |